imatinib has been researched along with axitinib in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 6 (85.71) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Giranda, VL; Johnson, EF; Luo, Y; Stewart, KD; Woods, KW | 1 |
| Ciceri, P; Davis, MI; Herrgard, S; Hocker, M; Hunt, JP; Pallares, G; Treiber, DK; Wodicka, LM; Zarrinkar, PP | 1 |
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP | 1 |
| Chen, C; Ge, J; Hu, C; Hu, Z; Huang, T; Jiang, Z; Li, L; Liu, J; Liu, Q; Liu, X; Ren, T; Wang, A; Wang, B; Wang, J; Wang, L; Wang, W; Wu, H; Xia, R; Zhang, Y | 1 |
| Malarz, K; Mularski, J; Musiol, R; Pacholczyk, M | 1 |
| Bai, M; Chen, C; Ge, J; Hu, C; Hu, Z; Jiang, Z; Liu, J; Liu, Q; Liu, X; Qi, Z; Ren, T; Wang, A; Wang, B; Wang, J; Wang, L; Wang, W; Yu, K; Zou, F | 1 |
7 other study(ies) available for imatinib and axitinib
| Article | Year |
|---|---|
Pharmacological and functional comparison of the polo-like kinase family: insight into inhibitor and substrate specificity.
Topics: Adenosine Triphosphate; Amino Acid Sequence; Androstadienes; Binding Sites; Cell Cycle Proteins; Humans; Models, Molecular; Molecular Sequence Data; Peptide Library; Polo-Like Kinase 1; Protein Conformation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Substrate Specificity; Wortmannin | 2007 |
Comprehensive analysis of kinase inhibitor selectivity.
Topics: Catalysis; Drug Design; Enzyme Stability; High-Throughput Screening Assays; Humans; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Signal Transduction; Substrate Specificity | 2011 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
The target landscape of clinical kinase drugs.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays | 2017 |
Discovery of (E)-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)propanamide (CHMFL-ABL-121) as a highly potent ABL kinase inhibitor capable of overcoming a variety of ABL mutants includi
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Female; Fusion Proteins, bcr-abl; Humans; Indazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Nude; Models, Molecular; Molecular Structure; Mutation; Neoplasms, Experimental; Piperazines; Protein Kinase Inhibitors; Pyridines; Structure-Activity Relationship | 2018 |
The p53 stabilizing agent CP-31398 and multi-kinase inhibitors. Designing, synthesizing and screening of styrylquinazoline series.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Design; Drug Screening Assays, Antitumor; Humans; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Stability; Pyrimidines; Quinazolines; Tumor Suppressor Protein p53 | 2019 |
Discovery of ( E)- N
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Design; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Indazoles; Mice; Models, Molecular; Molecular Docking Simulation; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship | 2019 |